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Introduction
The amyloid hypothesis proposes that large, protease-resistant 
amyloid fibers underlie the toxicity associated with several 
neurodegenerative diseases (Caughey and Lansbury, 2003; 
Chiti and Dobson, 2006). A definitive link between the amyloid 
aggregate and toxicity and neurodegeneration has not been 
established (Haass and Selkoe, 2007). A recent alternative 
proposal posits that an intermediate in the amyloid pathway is 
the primary toxic agent, while the large, insoluble aggregates 
may sequester oligomers and perhaps aid in cell survival 
(Kirkitadze et al., 2002). Soluble oligomers of several amyloido-
genic proteins including amyloid-, huntingtin, -synuclein, 
and PrP have been detected both from analysis of amyloid-
forming recombinant proteins and in cell and mouse models 
(Lasmézas et al., 1997; Conway et al., 1998; Tzaban et al., 
2002; Sánchez et al., 2003; Silveira et al., 2005; Lesné et al., 
2006; Sajnani et al., 2012). These oligomers, characterized 
as putative intermediates in amyloid formation, encompass a 
variety of sizes and structures that cause toxicity when intro-
duced into disease models (Klyubin et al., 2005; Silveira 
et al., 2005; Sajnani et al., 2012). Isolation of these dy-
namic, soluble oligomers has remained largely elusive and, 
as such, investigation of their role in amyloid formation has 
proven challenging.
The yeast prion protein Sup35 forms self-perpetuating 
amyloid conformers that are transmissible and infectious 
(Patino et al., 1996; Paushkin et al., 1996; Serio et al., 2000). 
To propagate the [PSI+] prion, Sup35 aggregates must un-
dergo remodeling by the chaperone Hsp104, which facilitates 
monomer addition by severing amyloid structures to generate 
transmissible species, or propagons (Chernoff et al., 1995; 
Kryndushkin et al., 2003; Shorter and Lindquist, 2006; Satpute-
Krishnan et al., 2007). Until now, in vivo studies have primar-
ily reported on the role of Hsp104 in aggregate fragmentation 
(Ness et al., 2002; Satpute-Krishnan et al., 2007). Interestingly, 
Hsp104 has also been shown to catalyze amyloid formation 
in vitro, specifically impacting the formation of amyloid oligo-
mers (Shorter and Lindquist, 2004). Moreover, recent in vitro 
evidence identified Sup35 oligomers as intermediates during 
amyloid formation under some conditions (Ohhashi et al., 
2010). Here, we identify soluble, more SDS-sensitive oligo-
mers of Sup35 as prion propagons and show that Hsp104 plays 
a role in their maintenance.
Amyloidogenic proteins aggregate through a self-templating mechanism that likely involves oligo-meric or prefibrillar intermediates. For disease- 
associated amyloidogenic proteins, such intermediates have 
been suggested to be the primary cause of cellular toxicity. 
However, isolation and characterization of these oligomeric 
intermediates has proven difficult, sparking controversy over 
their biological relevance in disease pathology. Here, we 
describe an oligomeric species of a yeast prion protein in 
cells that is sufficient for prion transmission and infectivity. 
These oligomers differ from the classic prion aggregates in 
that they are soluble and less resistant to SDS. We found 
that large, SDS-resistant aggregates were required for the 
prion phenotype but that soluble, more SDS-sensitive oligo-
mers contained all the information necessary to transmit the 
prion conformation. Thus, we identified distinct functional 
requirements of two types of prion species for this endoge-
nous epigenetic element. Furthermore, the nontoxic, self-
replicating amyloid conformers of yeast prion proteins have 
again provided valuable insight into the mechanisms of 
amyloid formation and propagation in cells.
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that the reduced activity of Hsp104-R830S impairs the mainte-
nance of the [PSI+] phenotype.
Next, we assessed the state of Sup35 in hsp104-R830S 
cryptic [PSI+] cells. We first performed sedimentation analysis 
with hsp104-R830S cryptic [PSI+] lysates and found that Sup35 
was soluble (Fig. 3 A). Next, we subjected lysates of hsp104-
R830S cryptic [PSI+] and HSP104 [psi] cells to sucrose gradi-
ent fractionation. Monomeric Sup35 in [psi] cells remained in 
the top fractions, while Sup35 from hsp104-R830S lysates was 
detected further down the gradient, demonstrating the existence 
of some oligomeric species (Fig. 3 B). To understand how these 
oligomers relate to the large SDS-resistant aggregates associated 
with the [PSI+] phenotype, we created a system to examine the 
effect of hsp104-R830S on pre-existing Sup35 aggregates. We 
covered hsp104-R830S cryptic [PSI+] with wild-type HSP104 
expressed from a glucose-repressible promoter such that cells 
grown in nonrepressing galactose allowed the propagation of 
[PSI+] and maintained SDS-resistant aggregates (Fig. 3 C, Gal). 
We then shifted the cells to glucose to repress wild-type HSP104 
(Fig. S3 A) and performed SDD-AGE to monitor the effect of 
hsp104-R830S on SDS-resistant Sup35 aggregates. Within 12 h 
of wild-type HSP104 repression, monomeric Sup35 was appar-
ent in hsp104-R830S cells. Within 24 h, SDS-resistant aggregates 
had disappeared (Fig. 3 C). As expected, when hsp104-R830S 
pGAL-HSP104 cells were switched from glucose back to 
galactose to de-repress wild-type HSP104, they became phe-
notypically [PSI+] (Fig. S3 B). Therefore, despite the loss of 
SDS-resistant aggregates, the propagons remained. Thus, the 
large SDS-resistant Sup35 aggregates are not strictly required for 
transmission of the prion.
We therefore reasoned that a less stable subpopulation of 
Sup35 might be capable of prion transmission. Indeed, that the 
addition of SDS to Sup35 prion aggregates results in smaller 
SDS-resistant polymers suggests that some less SDS-resistant 
species exists within the large prion aggregates (Kryndushkin 
et al., 2003). We investigated whether the soluble oligomers in 
hsp104-R830S cryptic [PSI+] cells were less resistant to SDS, 
as has been reported for another prion (Taneja et al., 2007). We 
again performed SDD-AGE on hsp104-R830S cryptic [PSI+] 
lysates but decreased the SDS concentration, and only then did 
we observe the presence of oligomeric species (Fig. 3 D). To 
determine how these species related to prion propagons and the 
cryptic [PSI+] phenotype, we repeated the wild-type HSP104 
repression time course with hsp104-R830S cells using a low-SDS 
SDD-AGE. We observed the maintenance of less SDS-resistant, 
oligomeric species throughout the time course (Fig. 3 E), suggest-
ing that the soluble, less SDS-resistant oligomers are the transmis-
sible propagons in hsp104-R830S cryptic [PSI+] cells.
Although we observed the unstable, soluble oligomers in 
the absence of insoluble aggregates, it is likely that both species 
exist in wild-type cells, and the more SDS-sensitive, soluble 
oligomers are more readily detectable in cells lacking insoluble 
aggregates. Therefore, we separated the Sup35 species in both 
hsp104-R830S cryptic [PSI+] and wild-type [PSI+] cells by su-
crose gradient and performed protein transformation to determine 
whether the soluble fractions contained infectious propagons. 
Both hsp104-R830S and HSP104 cells contained soluble Sup35 
Results and discussion
We performed a screen to identify cellular changes that res-
cued cells from toxic overexpression of SUP35 in [PSI+] cells 
(Vishveshwara et al., 2009). As this toxicity is dependent on 
[PSI+], we expected to uncover factors that affected Sup35 
aggregation. One mutation identified, hsp104-R830S in the 
C-terminal domain of Hsp104, caused [PSI+] cells to appear 
phenotypically [psi] by a readout of translation termination 
efficiency of a reporter that is indicative of the functional, 
soluble state of Sup35 (Fig. 1 A). Fluorescent imaging showed 
that Sup35 in hsp104-R830S cells appeared diffuse (Fig. 1 B), and 
by semi-denaturing detergent-agarose gel electrophoresis (SDD- 
AGE), only monomeric Sup35 was detected in hsp104-R830S 
cells (Fig. 1 C). Strikingly, mating hsp104-R830S cells that ap-
peared [psi] to wild-type HSP104 [psi] cells produced many 
diploids that were phenotypically [PSI+], as seen by increased 
nonsense suppression (Fig. S1). Furthermore, sporulation of these 
diploids produced two [PSI+] and two [psi] haploid progeny 
(Fig. 1 D), thereby indicating that prion-competent propagons 
had been maintained in hsp104-R830S cells that resulted in cryp-
tic [PSI+] (phenotypically undetectable). Indeed, transformation 
of hsp104-R830S cell lysates into wild-type [psi] cells demon-
strated that these propagons were infectious and produced [PSI+] 
cells. Out of 1,154 cells transformed, 45 were [PSI+] (3.9% in-
fectivity). Control transformations of [psi] lysates into [psi] 
cells resulted in only red colonies. Of the thousands of red colo-
nies resulting from these control transformations, over 400 were 
further analyzed and confirmed to be [psi]. Thus, the infectious 
propagon in hsp104-R830S cells is unable to cause observable 
nonsense suppression, but reestablishes and maintains the [PSI+] 
phenotype in the presence of wild-type HSP104.
Hsp104 normally functions to disaggregate nonprion ag-
gregates and promote cellular recovery from stress (Glover and 
Lindquist, 1998). Therefore, we tested the activity of the Hsp104-
R830S mutant with other known substrates. Interestingly, the 
thermotolerance of hsp104-R830S cells resembled that of wild-
type cells (Fig. 2 A). Moreover, hsp104-R830S cells efficiently 
resolubilized heat-aggregated luciferase (Fig. 2 B). Hsp104 
threads substrates through a central channel as a mechanism of 
disaggregation (Tessarz et al., 2008). The Hsp104 variant, HAP, 
has been used to investigate threading activity by coupling 
Hsp104 to the ClpP protease so that threaded substrates are 
degraded, resulting in decreased viability (Tessarz et al., 2008). 
We created the HAP-R830S variant and found that the mutant 
maintained threading activity (Fig. 2 C). Hsp104 is an AAA+ 
ATPase. Mutations that inhibit ATP hydrolysis or hexameriza-
tion typically prevent [PSI+] propagation (Glover and Lum, 
2009). We purified Hsp104-R830S and measured a reduced ini-
tial rate of ATP hydrolysis of 0.1659 ± 0.0308 nmol Pi·µg1·min1, 
as compared with the initial rate of wild-type Hsp104 of 0.2975 ± 
0.412 nmol Pi·µg1·min1, which is comparable to previously 
published data (Tkach and Glover, 2004). We next analyzed the 
distribution of Hsp104-R830S, relative to wild-type Hsp104, 
using glycerol gradients and size-exclusion chromatography. 
These analyses revealed that Hsp104-R830S forms unstable 
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Figure 1. hsp104-R830S propagates cryptic [PSI+]. (A) [PSI+], [psi], and hsp104-R830S cells were spotted on media containing CuSO4 to induce toxic 
overexpression of Sup35, media lacking adenine (SD-Ade) to assess nonsense suppression of the premature stop codon in ade1-14, and rich media (YPD). 
(B) HSP104 [PSI+] and hsp104-R830S cells containing pSup35NM-GFP were imaged by fluorescence microscopy. Bar, 10 µm. (C) Western blot of an 
SDS-containing agarose gel (SDD-AGE) shows Sup35 aggregate status in lysates of indicated strains. This blot is one representative of three individual 
experiments. (D) An example of two tetrads where mating hsp104-R830S to [psi] cells, both containing the ade1-14 mutation, resulted in tetrads with two 
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Propagons contain the variant-specific properties required 
for inheritance and propagation of distinct prion phenotypes 
(Tanaka et al., 2004; Satpute-Krishnan and Serio, 2005). There-
fore, the soluble oligomers in hsp104-R830S cryptic [PSI+] cells 
should retain the properties necessary to propagate the parental 
strong [PSI+] phenotype. If hsp104-R830S altered the prion struc-
ture, instead of cryptic [PSI+], weakened nonsense suppres-
sion and enhanced mitotic loss could be expected. After crossing 
hsp104-R830S cryptic [PSI+] cells to [psi] cells, we compared 
the [PSI+] meiotic progeny to the parental strong [PSI+] variant 
used initially in the screen. We found that the [PSI+] progeny were 
indeed strong [PSI+] phenotypically (Fig. 4 D). We then per-
formed SDD-AGE analysis of the resulting [PSI+] haploids as 
compared with the strong [PSI+] and a weak [PSI+] variant 
(Derkatch et al., 1996; Kryndushkin et al., 2003; Bagriantsev 
and Liebman, 2004). The SDS-resistant Sup35 aggregates in 
the [PSI+] progeny appear the same as strong [PSI+] (Fig. 4 E). 
We also noted that all the [PSI+] transformants from infection 
of hsp104-R830S lysates into [psi] cells were strong [PSI+]. 
Thus, Hsp104-R830S did not alter the properties of the original 
variant phenotypically or biochemically, suggesting that there 
was no change in prion structure.
oligomers that were infectious to [psi] cells (Fig. 4 A). 
Although much of the Sup35 species from wild-type lysates mi-
grated to the bottom of the gradient (35% of the total Sup35 
which correspond to 54% of the infectivity), there were highly 
infectious oligomers in wild-type [PSI+] cells that did not mi-
grate with the heavy-sedimenting aggregates. This soluble pool 
of Sup35 contains 46% of the infectivity in wild-type [PSI+] 
lysates. Curiously, the high-molecular weight aggregates ob-
served in hsp104-R830S cells were not very infectious, sug-
gesting that these aggregates are not the same high-molecular 
weight aggregates present in wild-type [PSI+] cells and are not 
efficient [PSI+] propagons. We then performed a simple solu-
bility assay to separate wild-type [PSI+] lysates into soluble 
and insoluble fractions (see Fig. 3 A), and then performed in-
fectivity assays and SDD-AGE analysis. Strikingly, we found 
much of the infectivity in the soluble fraction (32.8% of the 
total Sup35, which corresponds to 30% of the infectivity) from 
sedimentation analysis (Fig. 4 B). Additionally, by SDD-AGE, 
we found that there were no Sup35 oligomers resistant to 2% 
SDS in the soluble fraction (Fig. 4 C). As such, these data sup-
port our hypothesis that insoluble aggregates are not strictly re-
quired for prion transmission.
Figure 2. Analysis of Hsp104-R830S activity reveals the mechanism of altered activity. (A) Growth on YPD plates of the strains heat-shocked at 50°C for 
times indicated. Untreated cells were spotted before heat shock. (B) HSP104 (black), hsp104-R830S (red), and hsp104 (orange) cells expressing heat-
aggregatable luciferase were heat-shocked at 44°C while blocking new protein synthesis. Luminescence during recovery at 30°C was plotted as a fraction 
of luminescence before heat shock. Error bars represent the SD. (C) hsp104 cells carrying pRS315CUP1-ClpP, covered by the indicated plasmids, were 
spotted on media containing CuSO4 to induce expression of ClpP. (D) Hsp104 (top) and Hsp104-R830S (bottom) incubated with and without ATP (red/
black) separated on a glycerol gradient by ultracentrifugation. This is one representation of three individual experiments. The top of the gradient is fraction 











Published October 21, 2013
201Soluble oligomers maintain prions, not phenotype • Dulle et al.
[PSI+] cells are not required for prion transmission or infectivity. 
Furthermore, we have uncovered two novel features of yeast 
prion propagons. First, they can be more SDS sensitive, where 
previously only SDS-resistant aggregates of Sup35 were shown 
to be infectious (Bagriantsev et al., 2008). This sensitivity paral-
lels the previously described PK-sensitive PrP species, which 
We have shown, for the first time, the presence of soluble, 
prion-competent, less SDS-resistant oligomers of Sup35 in vivo. 
The less SDS-resistant, soluble oligomers are sufficient for trans-
mission of the prion conformation, but are not sufficient to pro-
duce the nonsense suppression phenotype associated with [PSI+]. 
We have also shown that the insoluble aggregates that characterize 
Figure 3. hsp104-R830S propagates SDS-
sensitive soluble oligomers of Sup35. (A) Ultra-
centrifugation separated lysates into total (T), 
soluble (S), and pellet (P) fractions. (B) Frac-
tionation of [psi] and hsp104-R830S cryptic 
[PSI+] lysates separated by a 3-h centrifugation 
through a linear sucrose gradient. (C) Hsp104 
and hsp104-R830S cells carrying p416GAL-
HSP104 grown in galactose were switched 
to glucose to repress p416GAL-HSP104, and 
p416GAL-HSP104 was efficiently repressed 
by 12 h in glucose as shown by Western blot 
in an hsp104 control (Fig. S3). Aliquots were 
taken from galactose and between 12 and 72 h 
in glucose and subjected to SDD-AGE. The 
shift in aggregate distribution occurs when 
changing carbon sources. (D) Lysates of the 
indicated strains were analyzed by SDD-AGE. 
The HSP104 [PSI+] and [psi] and hsp104-
R830S samples were incubated in sample 
buffer containing the indicated percentages of 
SDS. (E) Same as D, but samples were sub-
jected to SDD-AGE containing 0.01% SDS. 
All experiments were repeated at least three 
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can also transmit the prion (Sajnani et al., 2012). Second, soluble 
oligomers were able to act as propagons in vivo. Oligomers of sev-
eral amyloidogenic proteins have been described and can cause 
toxicity in the absence of large aggregates (Haass and Selkoe, 
2007). Indeed, our data correlate well with previous reports that 
visible Sup35 aggregates are lost in the mother cell and yet the 
prion is faithfully propagated (Taguchi and Kawai-Noma, 2010). 
Perhaps the SDS-resistant, insoluble Sup35 aggregates function 
as a reservoir for the continued renewal of transmissible propa-
gons. This role for SDS-resistant yeast prion aggregates mirrors 
the proposed role for amyloid aggregates as traps for oligomers 
(Kirkitadze et al., 2002). As such, we clearly show separate func-
tions of two distinct aggregate species that are structurally related 
components of the same prion propagation pathway. A mutant in 
Hsp104 enabled us to initially tease out these species. We favor 
a model whereby the decreased activity of hsp104-R830S results 
in reduced fragmentation of aggregates, but our data do not ex-
clude the possibility that Hsp104 normally plays a role in gener-
ating the large insoluble aggregates.
 The soluble oligomers that exist in many protein confor-
mational disorders are challenging to characterize due to their 
dynamic and metastable nature. In addition, conflicting reports 
on the properties and structure of oligomers complicate the elu-
cidation of the important oligomeric species (Haass and Selkoe, 
2007). The properties and mechanisms associated with yeast 
prion propagons may be similar to those associated with amy-
loidogenic proteins involved in self-propagating protein confor-
mational disorders. Therefore, investigating these features may 
lead to a better understanding of the function and structure of 
soluble, self-templating oligomers, as well as the role of amy-
loid in disease.
Materials and methods
Strains and yeast cultivation
The yeast strains used in this study are derivatives of Saccharomyces cerevi-
siae 74-D694 and were grown using standard culture techniques. YPD is 
rich yeast medium, whereas SD is synthetic medium lacking amino acids as 
needed to select for maintenance of plasmids or screen for a nonsense sup-
pression phenotype (SD-Ade). The strain used in the screen, 74-D694 [PSI+] 
can1::MFA1pr-HIS3-MFa1p r-LEU2 ade1-14 ura3-52 lys2::KanMX4 
pRS315CUP1-SUP35, was transformed with 10 independent plasmid pools 
Figure 4. Soluble oligomeric [PSI+] propagons are infectious and main-
tain the prion variant structure. (A) Fractions of [PSI+] and hsp104-R830S 
cryptic [PSI+] lysates separated on a linear sucrose gradient by a 22-h 
ultracentrifugation step were analyzed by Western blot and the amount of 
Sup35 (presented as the percent of soluble Sup35) in each fraction was 
quantified by ImageJ (National Institutes of Health) and is indicated below 
each fraction in the Western blot. Equal volumes of each fraction were 
transformed into [psi] cells. The fraction of infected [PSI+] cells obtained 
from each gradient fraction is indicated for hsp104-R830S (black) and 
HSP104 (gray) cells. The fraction of infected [PSI+] cells was generated by 
compiling the infectivity data from four (HSP104) or five (hsp104-R830S) 
separate sucrose gradients and transformations. Sup35 in hsp104-R830S 
lysates appears to be more susceptible to proteolysis and frequently shows 
degradation products. Protein molecular weight markers (kD) are indicated. 
(B) Total, soluble, and insoluble fractions of HSP104 [PSI+] lysates from 
sedimentation analysis were transformed into [psi] cells. The relative in-
fectivity of the total, soluble, and insoluble fractions was calculated as 
above and is indicated. (Inset) A Western blot for Sup35 in total (T), sol-
uble (S), and insoluble (I) fractions from one sedimentation assay in this 
experiment with protein molecular weight marker (kD). Of the thousands of 
red colonies resulting from transformation of the soluble and insoluble frac-
tions from wild-type [psi] cells as a negative control, further analysis veri-
fied that 48 from each fraction were [psi] in each of three independent 
experiments. (C) Total (T), soluble (S), and insoluble (I) fractions of HSP104 
[PSI+] lysates from sedimentation analysis were analyzed by SDD-AGE. 
The soluble fraction is from the top of the supernatant to prevent contami-
nation from the pellet. This experiment was repeated three times. (D) Two 
representative tetrads from the mating of hsp104-R830S cryptic [PSI+] to 
[psi] were spotted on YPD (top) and SD-Ade plates (bottom) to assess the 
level of nonsense suppression. Strong [PSI+] (Control A), weak [PSI+] (Con-
trol B), and [psi] (Control C) strains were spotted for reference. (E) The 
lysates of the four white haploids from the tetrads in C were analyzed by 
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5 min on ice before loading onto linear glycerol gradients (15–35%). The 
gradients were spun at 34,000 rpm for 18 h in a rotor (SW55; Beckman 
Coulter). Gradients were fractionated and the fractions analyzed by SDS-
PAGE and Western blot with anti-Hsp104 antibody.
Size-exclusion chromatography
Purified protein at 1 mg/ml was incubated in buffer (50 mM Tris, pH 7.5, 
200 mM KCl, 10 mM MgCl2, 2 mM DTT, and 2 mM EDTA) ± ATP for 
5 min. The sample was applied to an S-300HR column (GE Healthcare) 
and fractions were collected. The concentration of Hsp104 was measured 
by Bradford analysis (Bio-Rad Laboratories).
Thermotolerance assays
Cells were grown to mid-log phase at 30°C. An equal number of cells from 
each sample were aliquoted and pretreated at 37°C for 30 min. Samples 
were heat shocked at 50°C for the indicated amounts of time and then di-
luted fivefold before plating onto solid rich medium.
In vivo luciferase refolding assay
In vivo luciferase refolding assays were performed as described previously 
(Tipton et al., 2008). In brief, cells carrying pRS316GPD-Lux (provided by 
B. Bukau, ZMBH, Ruprecht-Karls-Universitat Heidelberg, Germany) were 
pretreated at 37°C for 1 h to induce expression of HSP104, then heat 
shocked at 44°C for 1 h. After 50 min of heat shock, cycloheximide was 
added to prevent new protein synthesis. After heat shock, the cells recover-
ing at 30°C were aliquoted at 15-min intervals and D-luciferin (Sigma- 
Aldrich) was added. Luminescence was measured and plotted as a 
percentage of total luciferase activity before heat shock.
Hsp104 shutoff experiments
The diploid strains, HSP104/hsp104::leu2 and HSP104/hsp104-R830S 
were transformed with pRS416GAL-HSP104, sporulated, and dissected on 
CSM-Ura + 0.25% galactose + 2% raffinose. Low levels of galactose were 
used to avoid curing [PSI+] by overexpression of HSP104. Progeny were se-
lected that contained the plasmid and were pink in color as evidence that 
[PSI+] was maintained. Cells were grown in CSM-Ura + 0.25% galactose + 
2% raffinose for 48 h before switching the cells to glucose media lacking ura-
cil to repress expression of the HSP104 plasmid. At 6-h intervals, aliquots of 
the sample were taken and both pelleted for SDD-AGE and plated on CSM-
Ura + 0.25% galactose + 2% raffinose plates. SDD-AGE was performed as 
described above. Gels were transferred to PVDF membrane and probed with 
anti-Sup35 antibody.
Sup35 solubility assays
Cells were lysed by bead-beating in buffer (10 mM NaPO4, pH 7.5, 250 mM 
NaCl, 2% SDS, 1% Triton X-100 plus mini EDTA-free protease inhibitors 
[Roche], and PMSF [Sigma-Aldrich]). Lysates were subjected to ultracentrifu-
gation at 100,000 rpm in a rotor (TLA-100; Beckman Coulter) for 1 h. The su-
pernatant was collected and the pellet resuspended in lysis buffer. Total, 
supernatant, and pellet fractions were subjected to SDS-PAGE and Western 
blot with anti-Sup35 antibody as well as protein transformation.
Sucrose gradients
Cells were lysed by bead-beating in buffer A. Total protein was normalized 
to 1 mg/ml and loaded onto a 4-mL linear sucrose gradient (15–60%) and 
centrifuged at 32,000 rpm for either 3 or 22 h. To compare infectivity of 
soluble and insoluble Sup35 from HSP104 [PSI+] by sucrose gradient, we 
increased the time of centrifugation to a time that reproducibly showed a 
large fraction of pelletable Sup35. Thus, after a 22-h spin, we are able to 
distinguish the soluble Sup35 and the insoluble Sup35 that migrates to the 
bottom of the gradient. Gradients were fractionated and the fractions were 
analyzed by SDS-PAGE, Western blot, and protein transformation.
Online supplemental material
Fig. S1 shows that the mating of hsp104-R830S cells to HSP104 [psi] cells 
results in cells that are phenotypically [PSI+]. Fig. S2 shows that Hsp104-
R830S forms unstable hexamers by size-exclusion chromatography. Fig. S3 A 
shows that growing the cells containing the pRS416-GAL-HSP104 construct 
in glucose efficiently represses wild-type HSP104 on the plasmid. Fig. S3 B 
shows that hsp104-R830S cells maintain [PSI+] propagons throughout the 
shutoff time course as de-repression of wild-type HSP104 results in pink 
[PSI+] colonies. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.201307040/DC1.
We thank J.R. Glover, B. Bukau, and J. Weissman for generously providing 
plasmids and protocols; and J. Cooper for use of his confocal microscope. 
of the mini-transposon (3XHA/lacZ(mTn3)) mutagenized library (provided 
by M. Snyder, Stanford University, Stanford, CA) and selected on media 
containing 350 µM copper sulfate to induce expression of SUP35. Candi-
dates that rescued toxicity associated with increased expression of SUP35 
were passaged a second time on copper sulfate media and were examined 
for the effect on [PSI+] phenotypically by color and genetically by mating to 
unmutagenized 74-D694 [PSI+] and [psi] isogenic strains. Several mu-
tants, not linked to the transposon, were analyzed and determined to be in 
Hsp104 through genetic analysis. The mutant characterized here, hsp104-
R830S, was recreated and these strains were used for further characteriza-
tion. Phenotypic assays are based on the amount of functional Sup35 to 
terminate the premature stop codon in ade1-14, which results in the accumu-
lation of a red-pigmented intermediate in the adenine biosynthesis pathway 
(Liebman and Derkatch, 1999).
SDD-AGE protein analysis
Cells were lysed by bead-beating in buffer A (25 mM Tris-HCl, pH 7.5, 
50 mM KCl, 10 mM MgCl2, 1 mM EDTA, 10% glycerol plus mini EDTA-free 
protease inhibitors [Roche], Aprotinen [Sigma-Aldrich], and PMSF [Sigma- 
Aldrich]). Samples were treated at room temperature for 7 min in sample 
buffer containing 2% SDS, then electrophoresed through a 0.1% SDS, 1.5% 
agarose gel. The gels were subjected to Western blot with anti-Sup35 anti-
body. The experiments done with lower SDS concentrations contained 0.01% 
SDS in the gel and between 0.05 and 0.1% SDS in the sample buffer, as 
indicated. Molecular weight markers were not used because nondenatured 
protein aggregates were being analyzed.
Fluorescence microscopy
Cells were transformed with pRS426CUP1-SUP35NM-GFP and grown in 
media lacking uracil. 50 µM CuSO4 was added to logarithmically growing 
cells and grown for 4 h to induce expression of SUP35NM-GFP. Images of 
cells expressing Sup35NM-GFP, in water and at room temperature, were 
captured on a microscope (Bmax-60F; Olympus) containing a 1.35 NA/100× 
UPlanApo objective lens, spinning disc Confocal Scanner Unit (CSU10), and 
an ICCD camera (XR-Mega10; Stanford Photonics). Images were acquired 
using QED software and analyzed by ImageJ (National Institutes of Health). 
In ImageJ, images were colored green for presentation.
Protein transformation
Recipient [psi] cells from logarithmically growing cultures were sphero-
plasted with lyticase. Samples from cell lysis, sedimentation analysis, and 
sucrose gradient fractionation were added to the spheroplasts in 1 M sor-
bitol along with a vector containing the URA3 gene for selection on media 
lacking uracil. The cells were incubated at room temperature then recov-
ered at 30°C. Media containing glucose, sorbitol, and agar was added to 
the cells before plating on sorbitol plates lacking uracil. Transformants 
were replica plated to YPD plates, and individual colonies were picked 
from those YPD plates and spotted onto YPD and both media lacking ade-
nine and containing GdHCl for quantification of infectivity.
Purification of Hsp104
Hsp104 was purified as described previously (Lum et al., 2004). Recombi-
nant Hsp104 tagged with a 6x-Histidine tag was expressed in Escherichia 
coli cells and affinity purified using a Ni2+-Sepharose column. Next, the 6x-
Histidine tag was removed by cleavage with the TEV protease and the un-
tagged Hsp104 was separated from the uncleaved, tagged Hsp104 by 
affinity purification. The untagged Hsp104 was further purified using anion 
exchange via a Q-Sepharose column. The pure Hsp104 collected from the 
Q-Sepharose column was then separated on an S-300 gel filtration column 
to isolate monomeric Hsp104. Purified, monomeric Hsp104 was pooled, 
concentrated, and frozen at 80°C. Multiple purification preparations were 
used for all assays in repeat experiments.
ATP hydrolysis assays
ATP hydrolysis was monitored by the Malachite Green assay. 2 µg purified 
Hsp104 was equilibrated in buffer (40 mM Tris-HCl, pH 7.5, 175 mM 
NaCl, 5 mM MgCl2, and 0.02% Triton X-100) at 37°C before adding 
5 mM ATP (Sigma-Aldrich). During incubation of Hsp104 with ATP at 
37°C, samples were taken and free phosphate was measured by addition 
of Malachite Green dye (Sigma-Aldrich). Color development occurred over 
1 min and was terminated by the addition of 34% citric acid (Sigma- 
Aldrich). Absorbance was measured at 650 nm.
Glycerol gradients
Purified protein at 75 µg was incubated in buffer (20 mM Tris, pH 8, 
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